Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
As an important sequela of the burgeoning global obesity problem, metabolic-associated fatty liver disease (MAFLD) has gained increasing prominence recently. The gut –liver axis (GLA) provides a direct conduit to the liver for the gut microbiota and their metabolic by-products (including secondary bile acids, ethanol, and trimethylamine). These GLA-related factors, including the host inflammatory response and integrity of the gut mucosal wall, likely contribut e to the pathogenesis of MAFLD. Accordingly, these GLA-related factors are targets for possible preventive and treatment strategies for MAFLD, and include probiotics, prebiotics, bile acids, short-chain fatty acids, fecal microbiota transplantation, carbon nanoparticles, and bacteriophages.
Source: Endocrinology and Metabolism Clinics of North America - Category: Endocrinology Authors: Thomas M. Barber, Petra Hanson, Martin O. Weickert Source Type: research
More News: Bile | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Liver Transplant | Nanotechnology | Obesity | Probiotics | Transplants | Trimethylamine | Urology & Nephrology